Delivery Order SPE2DR25D2206-SPE2DR26F9KD3
- Not listed
- The Defense Logistics Agency awarded a $19.2K delivery order to AmerisourceBergen Drug Corp (parent company Cencora, Inc.) on January 7, 2026, for the supply of Revlimid 10 mg capsules in quantities of 28 units. This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of January 29, 2026. The contract will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $51,681.12 to AmerisourceBergen Drug Corp for the supply of Revlimid 10 mg capsules (28-count units) on July 30, 2025, with an ultimate completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a discrete procurement action issued under...
- The Defense Logistics Agency awarded a $51,089.97 delivery order to AmerisourceBergen Drug Corp for Revlimid 10 mg capsules (28-count) on September 9, 2025, with performance completion targeted for September 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. AmerisourceBergen is a major pharmaceutical distributor and critical federal medical...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on December 2, 2025, for the supply of Revlimid 2.5 mg capsules (28-count packages) with a ceiling value of $14,450.99. This firm fixed-price delivery order, which is not set-aside designated, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999 through December 2026. The pharmaceutical supplies will...
- The Defense Logistics Agency awarded a $27,425.24 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Revlimid 2.5 mg capsules (28-count units), with an ultimate completion date of September 29, 2025. This non-set-aside competitive award was issued on September 8, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $97,728.21 to AmerisourceBergen Drug Corp for the supply of Revlimid 10 mg capsules (28-count units) on September 19, 2025, with an ultimate completion date of October 10, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and is being performed at the awardee's corporate office location in Conshohocken, Pennsylvania. The contract represents a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Revlimid 25 mg capsules (21-count unit) under a firm fixed-price contract with a ceiling value of $7,233.16. The order was competitively awarded without set-aside designation and is scheduled for completion by January 22, 2026. This delivery order is a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive global...
- The Defense Logistics Agency has awarded a delivery order valued at $51,879.46 to AmerisourceBergen Drug Corp for the supply of Revlimid 5 mg capsules (100-count units). This competitively awarded, firm fixed-price delivery order carries an ultimate completion date of September 26, 2025, and represents a non-set-aside procurement. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will perform this work at its corporate office location in...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 18, 2025, for the supply of Revlimid 5 mg capsules (100 count) with a ceiling value of $120,863.94. This firm fixed price delivery order is scheduled for completion by January 12, 2026, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting the contractor's established capability to...
- The Defense Logistics Agency awarded a $1.34 million delivery order to AmerisourceBergen Drug Corp on September 28, 2025, for the supply of Revlimid 10 mg capsules (100-count units). This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive process and scheduled for completion by October 20, 2025. The order will be fulfilled from AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters....
- SPE2DR25D2206Indefinite Delivery Contract
- SPE2DR25D2206-SPE2DR26F9KD3Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Revlimid 2.5 mg capsules (28-count units) valued at $20,846.38 on January 7, 2026, with completion by January 29, 2026. This firm fixed-price contract represents a non-set-aside award issued under open competition. The order will be fulfilled from the contractor's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order is issued as a task order under AmerisourceBergen's Indefinite Delivery Contract with DLA Troop Support Medical (valued at up to $1 billion through December 2026), which serves as a comprehensive global pharmaceutical support vehicle enabling supply of medications and medical commodities to military healthcare programs worldwide. The Revlimid order supports the Defense Health Agency and other government healthcare systems' ongoing pharmaceutical needs across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $20.8k | 1/6/26 |